-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $52

Benzinga·08/31/2026 14:29:03
Listen to the news
Leerink Partners analyst Thomas Smith initiates coverage on Attovia Therapeutics (NASDAQ:ATTO) with a Outperform rating and announces Price Target of $52.